avosentan

Ligand id: 8260

Name: avosentan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 133.8
Molecular weight 479.13
XLogP 3.36
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Avosentan entered Phase I clinical trial in 2001. The drug reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy, but induces significant fluid overload and congestive heart failure [2].